ID   ZR75-LTED
AC   CVCL_YX86
SY   ZR75 LTED; ZR75-Long Term Estrogen-Deprived
DR   cancercelllines; CVCL_YX86
DR   Wikidata; Q98136617
RX   PubMed=26116361;
CC   Population: Caucasian.
CC   Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 05-10-23; Version: 8
//
RX   PubMed=26116361; DOI=10.1158/1535-7163.MCT-15-0143;
RA   Ribas R., Pancholi S., Guest S.K., Marangoni E., Gao Q., Thuleau A.,
RA   Simigdala N., Polanska U.M., Campbell H., Rani A., Liccardi G.,
RA   Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.;
RT   "AKT antagonist AZD5363 influences estrogen receptor function in
RT   endocrine-resistant breast cancer and synergizes with fulvestrant
RT   (ICI182780) in vivo.";
RL   Mol. Cancer Ther. 14:2035-2048(2015).
//